Abstract
Breast cancer remains the most common oncological disease in women. Although the diagnostic and therapeutic advantages achieved in recent years have led to a decrease in the incidence of breast cancer-related deaths, metastatic breast cancer is still associated with an overall poor prognosis [1,2]. The therapy of metastatic breast cancer mainly focuses on control of symptoms and minimization of toxicities, with the aim of extending patients’ survival and maintaining quality of life. A number of agents, with different mechanisms of action, are available for the treatment of this complex disease. In particular, eribulin mesylate is a synthetic analog of halichondrin B, a natural product isolated from a marine sponge. Eribulin induces irreversible mitotic block and apoptosis by inhibiting microtubule polymerization [3]. The efficacy of this agent has been shown in the Phase III EMBRACE trial, which at present is the only trial in heavily treated breast cancer showing an advantage in overall survival [4]. Following the results of this trial, eribulin has been approved for the treatment of patients with metastatic breast cancer after anthracyclines and taxanes treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
